125 related articles for article (PubMed ID: 36789652)
1. Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
Ament CE; Steinmann S; Evert K; Pes GM; Ribback S; Gigante I; Pizzuto E; Banales JM; Rodrigues PM; Olaizola P; Wang H; Giannelli G; Chen X; Evert M; Calvisi DF
Hepatology; 2023 Dec; 78(6):1742-1754. PubMed ID: 36789652
[TBL] [Abstract][Full Text] [Related]
2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
[TBL] [Abstract][Full Text] [Related]
3. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
[TBL] [Abstract][Full Text] [Related]
4. Capsaicin suppresses the migration of cholangiocarcinoma cells by down-regulating matrix metalloproteinase-9 expression via the AMPK-NF-κB signaling pathway.
Lee GR; Jang SH; Kim CJ; Kim AR; Yoon DJ; Park NH; Han IS
Clin Exp Metastasis; 2014 Dec; 31(8):897-907. PubMed ID: 25217963
[TBL] [Abstract][Full Text] [Related]
5. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming.
Colyn L; Alvarez-Sola G; Latasa MU; Uriarte I; Herranz JM; Arechederra M; Vlachogiannis G; Rae C; Pineda-Lucena A; Casadei-Gardini A; Pedica F; Aldrighetti L; López-López A; López-Gonzálvez A; Barbas C; Ciordia S; Van Liempd SM; Falcón-Pérez JM; Urman J; Sangro B; Vicent S; Iraburu MJ; Prosper F; Nelson LJ; Banales JM; Martinez-Chantar ML; Marin JJG; Braconi C; Trautwein C; Corrales FJ; Cubero FJ; Berasain C; Fernandez-Barrena MG; Avila MA
J Exp Clin Cancer Res; 2022 May; 41(1):183. PubMed ID: 35619118
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
7. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
8. Slc35c2 promotes Notch1 fucosylation and is required for optimal Notch signaling in mammalian cells.
Lu L; Hou X; Shi S; Körner C; Stanley P
J Biol Chem; 2010 Nov; 285(46):36245-54. PubMed ID: 20837470
[TBL] [Abstract][Full Text] [Related]
9. Diethyldithiocarbamate suppresses an NF-kappaB dependent metastatic pathway in cholangiocarcinoma cells.
Srikoon P; Kariya R; Kudo E; Goto H; Vaeteewoottacharn K; Taura M; Wongkham S; Okada S
Asian Pac J Cancer Prev; 2013; 14(7):4441-6. PubMed ID: 23992017
[TBL] [Abstract][Full Text] [Related]
10. Terminal fucose mediates progression of human cholangiocarcinoma through EGF/EGFR activation and the Akt/Erk signaling pathway.
Indramanee S; Sawanyawisuth K; Silsirivanit A; Dana P; Phoomak C; Kariya R; Klinhom-On N; Sorin S; Wongkham C; Okada S; Wongkham S
Sci Rep; 2019 Nov; 9(1):17266. PubMed ID: 31754244
[TBL] [Abstract][Full Text] [Related]
11. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses.
Liu B; Yan S; Jia Y; Ma J; Wu S; Xu Y; Shang M; Mao A
FEBS J; 2016 Oct; 283(20):3839-3850. PubMed ID: 27616304
[TBL] [Abstract][Full Text] [Related]
12. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
[TBL] [Abstract][Full Text] [Related]
13. CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype.
Mancarella S; Serino G; Gigante I; Cigliano A; Ribback S; Sanese P; Grossi V; Simone C; Armentano R; Evert M; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Feb; 41(1):65. PubMed ID: 35172861
[TBL] [Abstract][Full Text] [Related]
14. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
15. YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice.
Lu X; Peng B; Chen G; Pes MG; Ribback S; Ament C; Xu H; Pal R; Rodrigues PM; Banales JM; Evert M; Calvisi DF; Chen X; Fan B; Wang J
Am J Pathol; 2021 Sep; 191(9):1651-1667. PubMed ID: 34129844
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of NF-κB in liver fluke associated cholangiocarcinoma: implications for targeted therapy.
Seubwai W; Wongkham C; Puapairoj A; Khuntikeo N; Pugkhem A; Hahnvajanawong C; Chaiyagool J; Umezawa K; Okada S; Wongkham S
PLoS One; 2014; 9(8):e106056. PubMed ID: 25170898
[TBL] [Abstract][Full Text] [Related]
17. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma.
Wang Y; Huang D; Chen KY; Cui M; Wang W; Huang X; Awadellah A; Li Q; Friedman A; Xin WW; Di Martino L; Cominelli F; Miron A; Chan R; Fox JG; Xu Y; Shen X; Kalady MF; Markowitz S; Maillard I; Lowe JB; Xin W; Zhou L
Gastroenterology; 2017 Jan; 152(1):193-205.e10. PubMed ID: 27639802
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
19. Expression levels and significance of nuclear factor-κB and epidermal growth factor receptor in hepatolithiasis associated with intrahepatic cholangiocarcinoma.
Zhou Q; Gong Y; Huang F; Lin Q; Zeng B; Li Z; Chen R
Dig Surg; 2013; 30(4-6):309-16. PubMed ID: 24008372
[TBL] [Abstract][Full Text] [Related]
20. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways.
Prakobwong S; Gupta SC; Kim JH; Sung B; Pinlaor P; Hiraku Y; Wongkham S; Sripa B; Pinlaor S; Aggarwal BB
Carcinogenesis; 2011 Sep; 32(9):1372-80. PubMed ID: 21325634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
